Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)
Pfizer predicts a $15B avalanche of cash from its Covid-19 vaccine in 2021 as the R&D team claims a big spike in the trial success rate
If anyone wants a lesson in the value of being first-in-class and best-in-class in the drug business, pick up a copy of Pfizer’s quarterly report today.
The pharma giant, long considered a lumbering behemoth in R&D, picked up a radical new mRNA vaccine from BioNTech for Covid-19 and just spiked the ball in the commercial end zone — all inside of a year. And they’ve already lined up enough contracts to back a pledge that this vaccine will bring in a total of $15 billion in 2021 alone — half of which they can keep.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters